Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Fay, Zohreh (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06987107
ABSTRACT:
Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)
orepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
REFERENCES:
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4596807 (1986-06-01), Crosby
patent: 5068433 (1991-11-01), Melloni et al.
patent: 5192751 (1993-03-01), Thor
patent: 5281624 (1994-01-01), Gehlert et al.
patent: 5391735 (1995-02-01), Melloni et al.
patent: 5441985 (1995-08-01), Foreman
patent: 5744474 (1998-04-01), Thor
patent: 5922914 (1999-07-01), Gage et al.
patent: 5998430 (1999-12-01), Schwantes et al.
patent: 6028070 (2000-02-01), Heiligenstein
patent: 6046193 (2000-04-01), Heiligenstein
patent: 6066643 (2000-05-01), Perry
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6479074 (2002-11-01), Murdock et al.
patent: 6572880 (2003-06-01), Murdock et al.
patent: 2014981 (1979-09-01), None
patent: 2167407 (1988-05-01), None
patent: WO 96/12485 (1996-05-01), None
patent: WO 97/35584 (1997-10-01), None
patent: WO 97/35586 (1997-10-01), None
patent: WO 99/11208 (1999-03-01), None
patent: WO99/15163 (1999-04-01), None
patent: WO99/15176 (1999-04-01), None
patent: WO99/15177 (1999-04-01), None
patent: WO 99/20279 (1999-04-01), None
patent: WO 99/52518 (1999-10-01), None
patent: WO 99/52531 (1999-10-01), None
patent: WO 99/58130 (1999-11-01), None
patent: WO 00/00120 (2000-01-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 01/47503 (2001-07-01), None
patent: WO 01/62236 (2001-08-01), None
J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders : A Review of Supporting Evidence, Am. J. of Psychiatry, vol. 122, pp. 509-522 (Nov. 1965).
T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: a-Receptor Mediation, Science, vol. 202, pp. 1089-1091 (1978).
E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake, Europ. J of Pharmacology, vol. 104 pp. 277-286 (1984).
C.B. Nemeroff, The Neurobiology of Depression, Scientific American (1988) (8 pages).
M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., vol. 1, No. 4, pp. 243-253 (1989).
T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, vol. 350, No. 28, pp. 350-356 (Mar. 1991).
M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, vol. 45, pp. 3-9 (1991).
E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, vol. 52, No. 6 Suppl., pp. 4-10 (Jun. 1991).
M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., vol. 326, No. 19, pp. 1250-1256 (1992).
B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Psychopharmacology, vol. 114, pp. 559-565 (1994).
M. Max, “Treatment of Post-Herpetic Neuralgia: Antidepressants,” Ann. Neurol., vol. 35, Suppl., pp. s50-s53 (1994).
W. Reimann et al., “Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol,” Biochem. Pharmacol., vol. 47, No. 12, pp. 2289-2293 (1994).
C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations, Biopharm. Drug Dispos. vol. 17. No. 7, pp. 623-633 (1996).
R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9thEd., Chapter 19, pp. 431-439, (1996).
B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S11-S16 (1997).
Discussion, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S71-S73 (1997).
S.A. Montgomery, Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S3-S9 (1997).
S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).
I. Hindmarch, The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, Vo. 7, Suppl. 1, pp. S17-S21 (1997).
E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, Chirality, vol. 9, pp. 303-306 (1997).
A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, vol. 17, No. 2, Suppl. 1, pp. 2S-18S (1997).
B. E. Leonard, The Role of Noradrenaline in Depression: a Review, J. Psychopharmacology, vol. II, No. 4 Suppl., pp. S39-S47 (1997).
Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor, Euro. Neuropsychopharmacol., vol. 7, Suppl. 1, pp. s23-s35 (1997).
M. Owens et al., “Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites,” J. Pharmacol. Exp. Ther., vol. 283, pp. 1305-1322 (1997).
D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, vol. 51, pp. 313-322 (1998).
Anonymous, Reboxetine—Another New Antidepressant, Drugs and Therapeutics Bull., 36 (11) (1998).
S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, vol. 59, Suppl. 14, pp. 26-29 (1998).
G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, vol. 59, Suppl. 14, 4 pages (1998).
J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, vol. 59, Suppl 14, pp. 8-10 (1998).
A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression, Eur. J. of Pharmacology, pp. 1-10 (1998).
J. Massana et al., Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, vol. 14, No. 2, pp. 73-80 (1999).
J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm. Drug Dispos. vol. 20, No. 1, pp. 53-57 (1999).
K. Moore et al., “Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality,” Am. J. of Forensic Med. and Path., vol. 20, No. 1, pp. 98-100 (1999).
S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, International Clinical Psychopharmacology, vol. 14, Suppl. 1, pp. S27-S31 (May 1999).
International Search Report in PCT/US00/17256 dated Jul. 12, 2001.
International Preliminary Examination Report in PCT/US00/17256 dated Dec. 19, 2001.
J. Mark Ruscin and Nora E. Morgenstern, “Tolterodine Use for Symptoms of Overactive Bladder,” The Annals of Pharmacotherapy, Abstract vol. 33, pp. 1073-1082 (Oct. 1999).
Mucci, M., “Reboxetine: A Review of Antidepressant Tolerability,”Journal of Psychopharmacology, Oxford University Press, 11(4):533-537 Supp, 1997.
Search Report in counterpart EP 04013383.7-2123, dated Jul. 22, 2004 (4 pages).
Ahmed Saeeduddin
Birgerson Lars
Marshall Robert C.
McArthur Robert
Taylor Duncan P.
Fay Zohreh
Marshall & Gerstein & Borun LLP
Pharmacia & Upjohn Company
LandOfFree
Method of treating incontinence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating incontinence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating incontinence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3524825